<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2026"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2026"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rvrc="http://reviumrx.com/20260630"
  xmlns:srt="http://fasb.org/srt/2026"
  xmlns:us-gaap="http://fasb.org/us-gaap/2026"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="rvrc-20260630.xsd" xlink:type="simple"/>
    <context id="cref_37844416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_360792440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1489499025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <instant>2026-06-10</instant>
        </period>
    </context>
    <context id="cref_1230631324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <startDate>2026-06-10</startDate>
            <endDate>2026-06-10</endDate>
        </period>
    </context>
    <context id="cref_1895697896">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2028-09-30</startDate>
            <endDate>2028-09-30</endDate>
        </period>
    </context>
    <context id="cref_1196774538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-04</startDate>
            <endDate>2026-03-04</endDate>
        </period>
    </context>
    <context id="cref_1409363158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-03-04</startDate>
            <endDate>2026-03-04</endDate>
        </period>
    </context>
    <context id="cref_849656553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1962214993">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_886712638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="cref_1206354996">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1308829283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1908462155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1904281717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rvrc:StatementOfIncomeLocationAxis">rvrc:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1135025880">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rvrc:StatementOfIncomeLocationAxis">rvrc:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1525589918">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rvrc:StatementOfIncomeLocationAxis">rvrc:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_2025729593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rvrc:StatementOfIncomeLocationAxis">rvrc:GeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_851776202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rvrc:StatementOfIncomeLocationAxis">rvrc:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1560896604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rvrc:StatementOfIncomeLocationAxis">rvrc:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_314568387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_762274639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_268231026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_801257943">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1128655509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1161306283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1968523848">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_1968975675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_995876555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_1525567919">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_331029226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="cref_1839481029">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="cref_1164130375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="cref_241004210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="cref_508427185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="cref_956248570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1959749533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1334402974">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_131536355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_862149152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_2084624905">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_2018492227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_2125055901">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_280997238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_922243596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_146813518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_1174470242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_508926862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1699846949">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_350625096">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_1322711708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_53208578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_756396576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_915325711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_856626706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1552314891">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_1516208607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_195295667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
        </entity>
        <period>
            <instant>2026-08-13</instant>
        </period>
    </context>
    <context id="cref_945780617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="cref_32597278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_321289872">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_868368166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1822080480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_797749636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_217271285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_710445909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-03-31</endDate>
        </period>
    </context>
    <context id="cref_2110781105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-03-31</instant>
        </period>
    </context>
    <context id="cref_141338480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="cref_2022146002">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_1944691220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="cref_431358788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="cref_792464826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rvrc:StatementOfIncomeLocationAxis">rvrc:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1131682909">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1737333020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-04-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <context id="cref_1919008100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2026-06-30</instant>
        </period>
    </context>
    <context id="cref_2138389447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_791989225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="cref_594754585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_802716902">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="cref_632163881">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001839140</identifier>
            <segment>
                <xbrldi:explicitMember dimension="rvrc:StatementOfIncomeLocationAxis">rvrc:ResearchAndDevelopmentExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2026-01-01</startDate>
            <endDate>2026-06-30</endDate>
        </period>
    </context>
    <unit id="uref_1006700557">
        <measure>pure</measure>
    </unit>
    <unit id="uref_1489499025">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="uref_1230631324">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="uref_1895697896">
        <measure>shares</measure>
    </unit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_945780617"
      id="fc_945780617"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_32597278"
      id="fc_32597278"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_321289872"
      id="fc_321289872"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_868368166"
      id="fc_868368166"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_1822080480"
      id="fc_1822080480"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="cref_360792440"
      id="fc_1716543744"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_797749636"
      id="fc_797749636"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_217271285"
      id="fc_217271285"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_710445909"
      id="fc_710445909"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_2110781105"
      id="fc_2110781105"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_141338480"
      id="fc_141338480"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_2022146002"
      id="fc_2022146002"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1944691220"
      id="fc_1944691220"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1334402974"
      id="fc_820828184"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1959749533"
      id="fc_1881154705"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_2022146002"
      id="fc_383101236"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1944691220"
      id="fc_1269583935"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_131536355"
      id="fc_1030479880"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_431358788"
      id="fc_431358788"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="cref_1308829283"
      id="fc_500136286"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <rvrc:PaymentsOfPropertyPlantAndEquipment
      contextRef="cref_360792440"
      id="fc_1344779890"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_792464826"
      id="fc_792464826"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_1206354996"
      id="fc_1272880275"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="cref_1962214993"
      id="fc_119015440"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="cref_1962214993"
      id="fc_892340636"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="cref_1962214993"
      id="fc_1096763520"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1131682909"
      id="fc_1131682909"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1737333020"
      id="fc_1737333020"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1174470242"
      id="fc_1818584584"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1131682909"
      id="fc_160265916"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1737333020"
      id="fc_1704499431"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_508926862"
      id="fc_648223013"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_1919008100"
      id="fc_1919008100"
      unitRef="uref_1895697896"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_1919008100"
      id="fc_989080370"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_2110781105"
      id="fc_1325849939"
      unitRef="uref_1895697896"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_945780617"
      id="fc_1730555209"
      unitRef="uref_1895697896"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_141338480"
      id="fc_56354474"
      unitRef="uref_1895697896"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_431358788"
      id="fc_1637502211"
      unitRef="uref_1895697896"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_2138389447"
      id="fc_2138389447"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_791989225"
      id="fc_791989225"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_995876555"
      id="fc_1845761172"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1968975675"
      id="fc_1008526115"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_2138389447"
      id="fc_1931821308"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_791989225"
      id="fc_1600145238"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1525567919"
      id="fc_1451102785"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:SharesOutstanding
      contextRef="cref_594754585"
      id="fc_594754585"
      unitRef="uref_1895697896"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_594754585"
      id="fc_1340557662"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_802716902"
      id="fc_802716902"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <rvrc:ExerciseOfOptionsIntoCommonStock
      contextRef="cref_360792440"
      id="fc_443709023"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <rvrc:ExerciseOfOptionsIntoCommonStock
      contextRef="cref_1308829283"
      id="fc_92646404"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_360792440"
      id="fc_915482341"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="cref_1308829283"
      id="fc_1330392028"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <rvrc:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiability
      contextRef="cref_1308829283"
      id="fc_1796942436"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_632163881"
      id="fc_632163881"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration contextRef="cref_360792440" id="fc_32209877">http://fasb.org/srt/2026#ChiefExecutiveOfficerMember</us-gaap:SegmentReportingExpenseInformationUsedByCodmTypeExtensibleEnumeration>
    <dei:SecurityExchangeName contextRef="cref_360792440" id="fc_712674496">NONE</dei:SecurityExchangeName>
    <us-gaap:PreferredStockValue
      contextRef="cref_314568387"
      id="fc_1635822238"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="cref_801257943"
      id="fc_900340926"
      unitRef="uref_1230631324"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey contextRef="cref_360792440" id="ixv-4494">0001839140</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="cref_360792440" id="ixv-4495">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="cref_360792440" id="ixv-4496">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="cref_360792440" id="ixv-4497">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:NoTradingSymbolFlag contextRef="cref_360792440" id="fc_1571747172">true</dei:NoTradingSymbolFlag>
    <dei:DocumentType contextRef="cref_360792440" id="ixv-5080">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="cref_360792440" id="ixv-5081">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="cref_360792440" id="ixv-5082">2026-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="cref_360792440" id="ixv-5083">2026</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="cref_360792440" id="ixv-5084">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="cref_360792440" id="ixv-5085">333-284934</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="cref_360792440" id="ixv-5086">REVIUM Rx.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="cref_360792440" id="ixv-5087">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="cref_360792440" id="ixv-5088">84-4516676</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="cref_360792440" id="ixv-5089">Azrieli Business Center 89</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="cref_360792440" id="ixv-5090">Medinat Hayehudim Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="cref_360792440" id="ixv-5091">Herzliya</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="cref_360792440" id="ixv-5092">IL</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="cref_360792440" id="ixv-5093">10017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="cref_360792440" id="ixv-5094">1800</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="cref_360792440" id="ixv-5095">519-1687</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus contextRef="cref_360792440" id="ixv-5096">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="cref_360792440" id="ixv-5097">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="cref_360792440" id="ixv-5098">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="cref_360792440" id="ixv-5099">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="cref_360792440" id="ixv-5100">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="cref_360792440" id="ixv-5101">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany contextRef="cref_360792440" id="ixv-5102">false</dei:EntityShellCompany>
    <dei:Security12bTitle contextRef="cref_360792440" id="ixv-5103">N/A</dei:Security12bTitle>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="cref_195295667"
      decimals="INF"
      id="ixv-5104"
      unitRef="uref_1895697896">60729100</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5105"
      unitRef="uref_1230631324">842000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5106"
      unitRef="uref_1230631324">1678000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5107"
      unitRef="uref_1230631324">664000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5108"
      unitRef="uref_1230631324">1033000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5109"
      unitRef="uref_1230631324">9000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5110"
      unitRef="uref_1230631324">9000</us-gaap:RestrictedCashCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5111"
      unitRef="uref_1230631324">341000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5112"
      unitRef="uref_1230631324">375000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5113"
      unitRef="uref_1230631324">1856000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5114"
      unitRef="uref_1230631324">3095000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5115"
      unitRef="uref_1230631324">9000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5116"
      unitRef="uref_1230631324">10000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5117"
      unitRef="uref_1230631324">172000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5118"
      unitRef="uref_1230631324">124000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5119"
      unitRef="uref_1230631324">2497000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5120"
      unitRef="uref_1230631324">2497000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5121"
      unitRef="uref_1230631324">2575000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5122"
      unitRef="uref_1230631324">2575000</us-gaap:Goodwill>
    <us-gaap:AssetsNoncurrent
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5123"
      unitRef="uref_1230631324">5253000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5124"
      unitRef="uref_1230631324">5206000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5125"
      unitRef="uref_1230631324">7109000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5126"
      unitRef="uref_1230631324">8301000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5127"
      unitRef="uref_1230631324">620000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5128"
      unitRef="uref_1230631324">163000</us-gaap:AccountsPayableCurrent>
    <rvrc:OtherAccountPayablesCurrent
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5129"
      unitRef="uref_1230631324">266000</rvrc:OtherAccountPayablesCurrent>
    <rvrc:OtherAccountPayablesCurrent
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5130"
      unitRef="uref_1230631324">575000</rvrc:OtherAccountPayablesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5131"
      unitRef="uref_1230631324">84000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5132"
      unitRef="uref_1230631324">60000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5133"
      unitRef="uref_1230631324">1000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:ConvertibleNotesPayableCurrent
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5134"
      unitRef="uref_1230631324">1000</us-gaap:ConvertibleNotesPayableCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5135"
      unitRef="uref_1230631324">971000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5136"
      unitRef="uref_1230631324">799000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5137"
      unitRef="uref_1230631324">44000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5138"
      unitRef="uref_1230631324">46000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="cref_314568387"
      decimals="-3"
      id="fc_2023873790"
      unitRef="uref_1230631324">575000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="cref_801257943"
      decimals="-3"
      id="fc_1949609532"
      unitRef="uref_1230631324">575000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5141"
      unitRef="uref_1230631324">619000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5142"
      unitRef="uref_1230631324">621000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5143"
      unitRef="uref_1230631324">1590000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5144"
      unitRef="uref_1230631324">1420000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="cref_314568387"
      decimals="3"
      id="ixv-5145"
      unitRef="uref_1489499025">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="cref_801257943"
      decimals="3"
      id="ixv-5146"
      unitRef="uref_1489499025">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_314568387"
      decimals="0"
      id="ixv-5147"
      unitRef="uref_1895697896">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="cref_801257943"
      decimals="0"
      id="ixv-5148"
      unitRef="uref_1895697896">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_314568387"
      decimals="3"
      id="ixv-5149"
      unitRef="uref_1489499025">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="cref_801257943"
      decimals="3"
      id="ixv-5150"
      unitRef="uref_1489499025">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_314568387"
      decimals="0"
      id="ixv-5151"
      unitRef="uref_1895697896">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="cref_801257943"
      decimals="0"
      id="ixv-5152"
      unitRef="uref_1895697896">250000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_314568387"
      decimals="0"
      id="ixv-5153"
      unitRef="uref_1895697896">60729100</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_314568387"
      decimals="0"
      id="ixv-5154"
      unitRef="uref_1895697896">60729100</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="cref_801257943"
      decimals="0"
      id="ixv-5155"
      unitRef="uref_1895697896">60729100</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="cref_801257943"
      decimals="0"
      id="ixv-5156"
      unitRef="uref_1895697896">60729100</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5157"
      unitRef="uref_1230631324">61000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5158"
      unitRef="uref_1230631324">61000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5159"
      unitRef="uref_1230631324">31893000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5160"
      unitRef="uref_1230631324">31782000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5161"
      unitRef="uref_1230631324">-26435000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5162"
      unitRef="uref_1230631324">-24962000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5163"
      unitRef="uref_1230631324">5519000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5164"
      unitRef="uref_1230631324">6881000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5165"
      unitRef="uref_1230631324">7109000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5166"
      unitRef="uref_1230631324">8301000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_37844416"
      decimals="-3"
      id="ixv-5167"
      unitRef="uref_1230631324">443000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_1908462155"
      decimals="-3"
      id="ixv-5168"
      unitRef="uref_1230631324">391000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5169"
      unitRef="uref_1230631324">916000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5170"
      unitRef="uref_1230631324">609000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_37844416"
      decimals="-3"
      id="ixv-5171"
      unitRef="uref_1230631324">289000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_1908462155"
      decimals="-3"
      id="ixv-5172"
      unitRef="uref_1230631324">547000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5173"
      unitRef="uref_1230631324">555000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5174"
      unitRef="uref_1230631324">1066000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_37844416"
      decimals="-3"
      id="ixv-5175"
      unitRef="uref_1230631324">-732000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_1908462155"
      decimals="-3"
      id="ixv-5176"
      unitRef="uref_1230631324">-938000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5177"
      unitRef="uref_1230631324">-1471000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5178"
      unitRef="uref_1230631324">-1675000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_37844416"
      decimals="-3"
      id="ixv-5179"
      unitRef="uref_1230631324">-16000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_1908462155"
      decimals="-3"
      id="ixv-5180"
      unitRef="uref_1230631324">-101000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5181"
      unitRef="uref_1230631324">-2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5182"
      unitRef="uref_1230631324">2000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="cref_37844416"
      decimals="-3"
      id="ixv-5183"
      unitRef="uref_1230631324">-748000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1908462155"
      decimals="-3"
      id="ixv-5184"
      unitRef="uref_1230631324">-1039000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5185"
      unitRef="uref_1230631324">-1473000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5186"
      unitRef="uref_1230631324">-1673000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_37844416"
      decimals="2"
      id="ixv-5187"
      unitRef="uref_1489499025">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_37844416"
      decimals="2"
      id="ixv-5188"
      unitRef="uref_1489499025">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1908462155"
      decimals="2"
      id="ixv-5189"
      unitRef="uref_1489499025">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1908462155"
      decimals="2"
      id="ixv-5190"
      unitRef="uref_1489499025">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_360792440"
      decimals="2"
      id="ixv-5191"
      unitRef="uref_1489499025">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_360792440"
      decimals="2"
      id="ixv-5192"
      unitRef="uref_1489499025">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1308829283"
      decimals="2"
      id="ixv-5193"
      unitRef="uref_1489499025">0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1308829283"
      decimals="2"
      id="ixv-5194"
      unitRef="uref_1489499025">0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_37844416"
      decimals="0"
      id="ixv-5195"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_37844416"
      decimals="0"
      id="ixv-5196"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1908462155"
      decimals="0"
      id="ixv-5197"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1908462155"
      decimals="0"
      id="ixv-5198"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_360792440"
      decimals="0"
      id="ixv-5199"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_360792440"
      decimals="0"
      id="ixv-5200"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1308829283"
      decimals="0"
      id="ixv-5201"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1308829283"
      decimals="0"
      id="ixv-5202"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:SharesOutstanding
      contextRef="cref_1516208607"
      decimals="INF"
      id="ixv-5203"
      unitRef="uref_1895697896">60729100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_1516208607"
      decimals="-3"
      id="ixv-5204"
      unitRef="uref_1230631324">61000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_1552314891"
      decimals="-3"
      id="ixv-5205"
      unitRef="uref_1230631324">31782000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_856626706"
      decimals="-3"
      id="ixv-5206"
      unitRef="uref_1230631324">-24962000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5207"
      unitRef="uref_1230631324">6881000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="cref_915325711"
      decimals="-3"
      id="ixv-5208"
      unitRef="uref_1230631324">-725000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_756396576"
      decimals="-3"
      id="ixv-5209"
      unitRef="uref_1230631324">-725000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="cref_146813518"
      decimals="INF"
      id="ixv-5210"
      unitRef="uref_1895697896">60729100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_53208578"
      decimals="-3"
      id="ixv-5211"
      unitRef="uref_1230631324">61000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_1322711708"
      decimals="-3"
      id="ixv-5212"
      unitRef="uref_1230631324">31782000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_350625096"
      decimals="-3"
      id="ixv-5213"
      unitRef="uref_1230631324">-25687000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_1699846949"
      decimals="-3"
      id="ixv-5214"
      unitRef="uref_1230631324">6156000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="cref_508926862"
      decimals="-3"
      id="ixv-5215"
      unitRef="uref_1230631324">-748000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_37844416"
      decimals="-3"
      id="ixv-5216"
      unitRef="uref_1230631324">-748000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1174470242"
      decimals="-3"
      id="ixv-5217"
      unitRef="uref_1230631324">111000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_37844416"
      decimals="-3"
      id="ixv-5218"
      unitRef="uref_1230631324">111000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:SharesOutstanding
      contextRef="cref_146813518"
      decimals="0"
      id="ixv-5219"
      unitRef="uref_1895697896">60729100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_146813518"
      decimals="-3"
      id="ixv-5220"
      unitRef="uref_1230631324">61000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_922243596"
      decimals="-3"
      id="ixv-5221"
      unitRef="uref_1230631324">31893000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_280997238"
      decimals="-3"
      id="ixv-5222"
      unitRef="uref_1230631324">-26435000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5223"
      unitRef="uref_1230631324">5519000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding
      contextRef="cref_2125055901"
      decimals="INF"
      id="ixv-5224"
      unitRef="uref_1895697896">60729100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_2125055901"
      decimals="-3"
      id="ixv-5225"
      unitRef="uref_1230631324">61000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_2018492227"
      decimals="-3"
      id="ixv-5226"
      unitRef="uref_1230631324">30388000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_2084624905"
      decimals="-3"
      id="ixv-5227"
      unitRef="uref_1230631324">770000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_862149152"
      decimals="-3"
      id="ixv-5228"
      unitRef="uref_1230631324">-11513000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_268231026"
      decimals="-3"
      id="ixv-5229"
      unitRef="uref_1230631324">19706000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="cref_131536355"
      decimals="-3"
      id="ixv-5230"
      unitRef="uref_1230631324">-634000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_956248570"
      decimals="-3"
      id="ixv-5231"
      unitRef="uref_1230631324">-634000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1334402974"
      decimals="-3"
      id="ixv-5232"
      unitRef="uref_1230631324">301000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1959749533"
      decimals="-3"
      id="ixv-5233"
      unitRef="uref_1230631324">39000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_956248570"
      decimals="-3"
      id="ixv-5234"
      unitRef="uref_1230631324">340000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:SharesOutstanding
      contextRef="cref_508427185"
      decimals="INF"
      id="ixv-5235"
      unitRef="uref_1895697896">60729100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_508427185"
      decimals="-3"
      id="ixv-5236"
      unitRef="uref_1230631324">61000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_241004210"
      decimals="-3"
      id="ixv-5237"
      unitRef="uref_1230631324">30689000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_1164130375"
      decimals="-3"
      id="ixv-5238"
      unitRef="uref_1230631324">809000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_1839481029"
      decimals="-3"
      id="ixv-5239"
      unitRef="uref_1230631324">-12147000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_331029226"
      decimals="-3"
      id="ixv-5240"
      unitRef="uref_1230631324">19412000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1525567919"
      decimals="-3"
      id="ixv-5241"
      unitRef="uref_1230631324">-1039000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1908462155"
      decimals="-3"
      id="ixv-5242"
      unitRef="uref_1230631324">-1039000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_995876555"
      decimals="-3"
      id="ixv-5243"
      unitRef="uref_1230631324">963000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1968975675"
      decimals="-3"
      id="ixv-5244"
      unitRef="uref_1230631324">-809000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="cref_1908462155"
      decimals="-3"
      id="ixv-5245"
      unitRef="uref_1230631324">154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:SharesOutstanding
      contextRef="cref_1968523848"
      decimals="0"
      id="ixv-5246"
      unitRef="uref_1895697896">60729100</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_1968523848"
      decimals="-3"
      id="ixv-5247"
      unitRef="uref_1230631324">61000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_1161306283"
      decimals="-3"
      id="ixv-5248"
      unitRef="uref_1230631324">31652000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_1128655509"
      decimals="-3"
      id="ixv-5249"
      unitRef="uref_1230631324">-13186000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="cref_762274639"
      decimals="-3"
      id="ixv-5250"
      unitRef="uref_1230631324">18527000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5251"
      unitRef="uref_1230631324">-1473000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5252"
      unitRef="uref_1230631324">-1673000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5253"
      unitRef="uref_1230631324">2000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5254"
      unitRef="uref_1230631324">1000</us-gaap:Depreciation>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5255"
      unitRef="uref_1230631324">111000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5256"
      unitRef="uref_1230631324">494000</us-gaap:ShareBasedCompensation>
    <rvrc:FinanceIncome
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5257"
      unitRef="uref_1230631324">-19000</rvrc:FinanceIncome>
    <rvrc:FinanceIncome
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5258"
      unitRef="uref_1230631324">11000</rvrc:FinanceIncome>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5259"
      unitRef="uref_1230631324">-34000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5260"
      unitRef="uref_1230631324">-4000</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5261"
      unitRef="uref_1230631324">-309000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInOtherAccountsPayable
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5262"
      unitRef="uref_1230631324">22000</us-gaap:IncreaseDecreaseInOtherAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5263"
      unitRef="uref_1230631324">457000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5264"
      unitRef="uref_1230631324">47000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <rvrc:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiability
      contextRef="cref_360792440"
      decimals="-3"
      id="fc_1732511263"
      unitRef="uref_1230631324">-8000</rvrc:IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5266"
      unitRef="uref_1230631324">-1167000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5267"
      unitRef="uref_1230631324">-1116000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5268"
      unitRef="uref_1230631324">-350000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5269"
      unitRef="uref_1230631324">-1500000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5270"
      unitRef="uref_1230631324">19000</us-gaap:PaymentsToAcquireInvestments>
    <rvrc:PaymentsOfPropertyPlantAndEquipment
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5271"
      unitRef="uref_1230631324">4000</rvrc:PaymentsOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5272"
      unitRef="uref_1230631324">331000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5273"
      unitRef="uref_1230631324">1496000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5274"
      unitRef="uref_1230631324">-836000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5275"
      unitRef="uref_1230631324">380000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_801257943"
      decimals="-3"
      id="ixv-5276"
      unitRef="uref_1230631324">1678000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_268231026"
      decimals="-3"
      id="ixv-5277"
      unitRef="uref_1230631324">3268000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5278"
      unitRef="uref_1230631324">842000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="cref_762274639"
      decimals="-3"
      id="ixv-5279"
      unitRef="uref_1230631324">3648000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="cref_360792440" id="ixv-2621">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 1&lt;/span&gt;:- &lt;span style="font-weight: bold;"&gt;GENERAL&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 82pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 24px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;a.&lt;/span&gt;&lt;/td&gt; &lt;td style="text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Revium Rx (&#x201c;Revium&#x201d;     or &#x201c;Company&#x201d;), previously known as Revium Recovery Inc., was incorporated in the State of Delaware on January 24, 1997,     under the name &#x201c;Fun Cosmetic, Inc.&#x201d; &#160;On August 29, 2005, it changed its name to Grand Canal Entertainment, Inc.     On October 14, 2008, the Company merged with OC Beverage, Inc. a Nevada corporation, a manufacturer of beverages, and on October     31, 2008 it subsequently changed its name to OC Beverages, Inc. On June 22, 2020, the Company formed a wholly owned Israeli subsidiary     called Revium Recovery Ltd. (the &#x201c;Subsidiary&#x201d;). On December 4, 2020, the Company changed its name to Revium Recovery     Inc.&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt; &lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;On December 17, 2024, the Company completed the redomicile from the State of Delaware to the State of Nevada (the &#x201c;Reincorporation&#x201d;). As a result of the Reincorporation, the Company ceased its business existence as a Delaware corporation and continued its business existence as a Nevada corporation under the name &#x201c;Revium Rx.&#x201d;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;In November 2023, the Company entered into a stock exchange agreement (&#x201c;Share Exchange&#x201d;) with Lipovation Ltd, a private Israeli company engaged in the development of novel pharmaceutical solutions (&#x201c;Lipovation&#x201d; or the &#x201c;Predecessor&#x201d;). Following the closing of such agreement on July 23, 2024, the Predecessor became a new wholly owned subsidiary of the Company, and as determined by the Company&#x2019;s board of directors. Following the closing of the Share Exchange agreement, the Company&#x2019;s Board of Directors determined to discontinue all of the Company&#x2019;s prior activities and efforts in the development and activation of the clinical decision-making support system which constituted the business of the Company prior to the closing of the stock exchange agreement, and to focus on the development of the acquired LipoVation&#x2019;s business.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Through its subsidiary LipoVation Ltd, the Company is developing novel lipid-based therapies for infectious diseases and cancer, with a focus on improving drug delivery, therapeutic exposure, and treatment effectiveness. Through its subsidiaries, the Company is advancing a pipeline of proprietary liposomal drug candidates, including a systemic liposomal antibiotic intended to target drug-resistant pathogens such as MRSA, VRSA, and N. gonorrhoeae, as well as other liposomal therapies intended to improve the efficacy and tolerability of treatments for oncology and infectious disease indications.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 24px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;b.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Going concern and management plans:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The Company is in the research and development (R&amp;amp;D) stage and, as such, has not generated any revenue from its current operations. The Company&#x2019;s activities are primarily funded through investment. As of June 30, 2026, the Company reported an accumulated deficit of $26,435.&lt;/span&gt; &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;To support its operations and advance its development programs, the Company intends to continue securing investments. Management anticipates that additional capital will be necessary to fund its ongoing R&amp;amp;D activities and to explore opportunities for acquiring healthcare or healthcare-related technologies. However, there are currently no binding commitments for further investment, and there can be no assurance that the Company will secure the required capital on commercially reasonable terms, or at all.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;If sufficient investment cannot be obtained, the Company may need to implement cost-cutting measures, scale back its R&amp;amp;D activities, or delay certain development programs. These factors&#160;raise substantial doubt&#160;about the Company&#x2019;s ability to continue as a going concern. The interim condensed consolidated financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company were unable to continue as a going concern.&lt;/span&gt;&lt;/p&gt;             &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 24px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 24px;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;c.&lt;/span&gt;&lt;/td&gt; &lt;td&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Impact of War on Israel:&lt;/span&gt;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;On June 13, 2025, in light of continued nuclear threats and intelligence assessments indicating imminent attacks, Israel launched a pre-emptive strike directly targeting military and nuclear infrastructure inside Iran aimed to disrupt Iran&#x2019;s capacity to coordinate or launch further hostilities against Israel, as well as disrupt its nuclear program. On June 25, 2025, a ceasefire between Israel and Iran took effect. Nonetheless, hostilities between Israel and Iran may resume and further escalate, with both sides launching attacks against one another. Company&#x2019;s subsidiaries experienced disruptions to their work during such period. Since June 25, 2025, The Company&#x2019;s subsidiaries have been returning to full activity together with its local vendors and consultants.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Since early 2026, the conflict involving Iran and Israel has intensified into a broader regional confrontation, with Iran and Israel exchanging missile, drone, and air strikes, and with related hostilities also involving Hezbollah in Lebanon, the Houthis in Yemen, and other Iran-aligned groups across the region. Recent reporting indicates that the conflict remains volatile and fluid, with continued diplomatic efforts and the potential for renewed escalation if a lasting arrangement is not reached.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;While this prolonged regional conflict has not had a direct material financial impact on the Company as of the date of this financial statements, the Company&#x2019;s headquarters are located in Israel, and the Company employs several professionals in Israel, including the majority of the Company&#x2019;s senior leadership team. The Company continues to actively monitor developments in Israel, Iran, and the broader region, including the possible effects of renewed hostilities, security disruptions, and related operational, supply chain, and personnel risks.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The Company continues to monitor its ongoing activities and will make adjustments in its business if needed, including updating any estimates or judgments impacting its financial statements as appropriate.&lt;/span&gt;&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <dei:EntityIncorporationDateOfIncorporation contextRef="cref_360792440" id="ixv-5280">1997-01-24</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="cref_314568387"
      decimals="-3"
      id="ixv-5281"
      unitRef="uref_1230631324">-26435000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="cref_360792440" id="ixv-2728">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 2&lt;/span&gt;: - &lt;span style="font-weight: bold;"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and accompanying notes for the year ended December 31, 2025. The significant accounting policies applied in the annual financial statements of the Company as of December 31, 2025, are applied consistently in these interim consolidated financial statements.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Recently issued accounting pronouncements. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which the Company adopted for the annual period ended December 31, 2025 and applies to its interim reporting from January 1, 2026. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, effective for annual periods beginning after December 15, 2024, and in November 2024 the FASB issued ASU 2024-03, Income Statement &#x2014; Reporting Comprehensive Income &#x2014; Expense Disaggregation Disclosures (Subtopic 220-40), effective for annual periods beginning after December 15, 2026 and interim periods beginning after December 15, 2027. The Company is evaluating the effect of these standards and does not currently expect their adoption to have a material effect on its financial position or results of operations. Other accounting pronouncements issued but not yet effective are not expected to have a material effect on the Company&#x2019;s interim condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:QuarterlyFinancialInformationTextBlock contextRef="cref_360792440" id="ixv-2760">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 3 &#x2013; UNAUDITED INTERIM FINANCIAL STATEMENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The accompanying interim consolidated balance sheet as of June 30, 2026, the interim consolidated statements of comprehensive loss for the three and six months ended June 30, 2026, and 2025, and the interim consolidated statements of cash flows for the six months ended June 30, 2026, and 2025, as well as the interim consolidated statements of changes in equity for the six months ended June 30, 2026, and 2025 are unaudited.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;These unaudited interim consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States (&#x201c;U.S. GAAP&#x201d;) and applicable rules and regulations of the Securities and Exchange Commission regarding interim financial reporting. In management&#x2019;s opinion, the unaudited interim consolidated financial statements include all adjustments of a normal recurring nature necessary for the fair presentation of the Company&#x2019;s financial position as of June 30, 2026, as well as its results of operations and cash flows for the three and six months ended June 30, 2026, and 2025. The results of operations for the three and six months ending June 30, 2026, are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2026.&lt;/span&gt;&lt;/p&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="cref_360792440" id="ixv-2775">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: -56.7pt;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 4: -BASIC AND DILUTED LOSS PER SHARE:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Basic loss per share is computed by dividing the net loss available to common shareholders by the weighted average number of shares outstanding during the reporting period. Diluted loss per share is computed similarly to basic loss per share except that the weighted average number of shares outstanding is increased to include additional shares from the assumed exercise of stock options and warrants, if dilutive. The average number of shares is calculated by assuming that outstanding conversions were exercised and that the proceeds from such exercises were used to acquire common shares at the average market price during the reporting period, potentially dilutive common shares issuable upon the exercise of warrants and options were not included in the computation of loss per share because their effect was anti-dilutive&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The loss and the weighted average number of shares used in computing basic and diluted net loss per share for the three and six months periods ended June 30, 2026 and 2025, are as follows:&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; three months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; three months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; six months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; six months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Unaudited&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Numerator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;Net loss applicable to shareholders of Ordinary Share&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;748&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,039&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,473&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,673&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;Denominator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Shares of Ordinary Share used in computing basic and diluted net loss per share&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;60,729,100&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;60,729,100&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;60,729,100&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;60,729,100&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Net loss per share of Ordinary Share, basic and diluted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.01&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.02&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.02&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.03&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="cref_360792440" id="ixv-2785">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The loss and the weighted average number of shares used in computing basic and diluted net loss per share for the three and six months periods ended June 30, 2026 and 2025, are as follows:&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; three months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; three months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; six months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; six months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Unaudited&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;Numerator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;Net loss applicable to shareholders of Ordinary Share&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;748&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,039&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,473&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;1,673&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;Denominator:&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left;"&gt;Shares of Ordinary Share used in computing basic and diluted net loss per share&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;60,729,100&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;60,729,100&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;60,729,100&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;60,729,100&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="text-align: left;"&gt;Net loss per share of Ordinary Share, basic and diluted&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.01&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.02&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.02&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;0.03&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="cref_37844416"
      decimals="-3"
      id="ixv-5282"
      unitRef="uref_1230631324">-748000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1908462155"
      decimals="-3"
      id="ixv-5283"
      unitRef="uref_1230631324">-1039000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5284"
      unitRef="uref_1230631324">-1473000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5285"
      unitRef="uref_1230631324">-1673000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_37844416"
      decimals="0"
      id="ixv-5286"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_37844416"
      decimals="0"
      id="ixv-5287"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1908462155"
      decimals="0"
      id="ixv-5288"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1908462155"
      decimals="0"
      id="ixv-5289"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_360792440"
      decimals="0"
      id="ixv-5290"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_360792440"
      decimals="0"
      id="ixv-5291"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="cref_1308829283"
      decimals="0"
      id="ixv-5292"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="cref_1308829283"
      decimals="0"
      id="ixv-5293"
      unitRef="uref_1895697896">60729100</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_37844416"
      decimals="2"
      id="ixv-5294"
      unitRef="uref_1489499025">0.01</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_37844416"
      decimals="2"
      id="ixv-5295"
      unitRef="uref_1489499025">0.01</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1908462155"
      decimals="2"
      id="ixv-5296"
      unitRef="uref_1489499025">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1908462155"
      decimals="2"
      id="ixv-5297"
      unitRef="uref_1489499025">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_360792440"
      decimals="2"
      id="ixv-5298"
      unitRef="uref_1489499025">0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_360792440"
      decimals="2"
      id="ixv-5299"
      unitRef="uref_1489499025">0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="cref_1308829283"
      decimals="2"
      id="ixv-5300"
      unitRef="uref_1489499025">0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="cref_1308829283"
      decimals="2"
      id="ixv-5301"
      unitRef="uref_1489499025">0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="cref_360792440" id="ixv-2965">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 5 &#x2013; SHAREHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Share-based expenses recognized in the financial statements:&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; three months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; three months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; six months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; six months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Unaudited&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;Research and development expenses&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_792464826;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;11&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_632163881;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;103&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;General and administrative expenses&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;111&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;143&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;111&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;391&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;111&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;154&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;111&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;494&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Unaudited&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Number of &lt;br/&gt; options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; terms&lt;br/&gt; (in years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: justify;"&gt;Outstanding as of January 1, 2026&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4,270,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0.30&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4.90&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1272880275;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Exercised&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(740,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;0.30&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Outstanding at June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,530,000&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;0.30&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;2.67&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_119015440;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Vested and expected to vest at June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,530,000&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;0.30&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;2.67&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_892340636;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Exercisable as of June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,530,000&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;0.30&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;2.67&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1096763520;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&#160;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;On March 4, 2026, a former employee of the Company exercised 740,000 options on a cashless basis into 592,000 shares of common stock of the Company. As of the balance sheet date, the shares had not yet been issued.&lt;/span&gt; &lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="cref_360792440" id="ixv-2972">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Share-based expenses recognized in the financial statements:&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; three months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; three months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; six months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center;"&gt;For the &lt;br/&gt; six months &lt;br/&gt; ended&lt;br/&gt; June 30,&lt;/td&gt; &lt;td style="font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2026&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;2025&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Unaudited&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: left;"&gt;Research and development expenses&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_792464826;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;11&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_632163881;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;103&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;General and administrative expenses&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;111&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;143&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;111&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;391&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;Total&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;111&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;154&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;111&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;494&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1560896604"
      decimals="-3"
      id="ixv-5302"
      unitRef="uref_1230631324">11000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_851776202"
      decimals="-3"
      id="ixv-5303"
      unitRef="uref_1230631324">103000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_2025729593"
      decimals="-3"
      id="ixv-5304"
      unitRef="uref_1230631324">111000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1525589918"
      decimals="-3"
      id="ixv-5305"
      unitRef="uref_1230631324">143000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1135025880"
      decimals="-3"
      id="ixv-5306"
      unitRef="uref_1230631324">111000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1904281717"
      decimals="-3"
      id="ixv-5307"
      unitRef="uref_1230631324">391000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_37844416"
      decimals="-3"
      id="ixv-5308"
      unitRef="uref_1230631324">111000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1908462155"
      decimals="-3"
      id="ixv-5309"
      unitRef="uref_1230631324">154000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5310"
      unitRef="uref_1230631324">111000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="cref_1308829283"
      decimals="-3"
      id="ixv-5311"
      unitRef="uref_1230631324">494000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="cref_360792440" id="ixv-3113">&lt;table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif;"&gt; &lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="14" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Unaudited&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Number of &lt;br/&gt; options&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted &lt;br/&gt; average &lt;br/&gt; exercise &lt;br/&gt; price&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Weighted&lt;br/&gt; average&lt;br/&gt; remaining&lt;br/&gt; contractual&lt;br/&gt; terms&lt;br/&gt; (in years)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid;"&gt;Aggregate&lt;br/&gt; intrinsic&lt;br/&gt; value&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2" style="text-align: center;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td colspan="2"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt; &lt;td style="width: 52%; text-align: justify;"&gt;Outstanding as of January 1, 2026&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4,270,000&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;0.30&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;4.90&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="width: 9%; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1272880275;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="width: 1%; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 1.5pt;"&gt;Exercised&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;(740,000&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;)&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;0.30&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 1.5pt solid; text-align: right;"&gt;-&lt;/td&gt; &lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Outstanding at June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,530,000&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;0.30&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;2.67&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_119015440;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Vested and expected to vest at June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,530,000&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;0.30&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;2.67&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_892340636;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255);"&gt;&lt;td style="text-align: justify;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: right;"&gt;&#160;&lt;/td&gt; &lt;td style="text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: White;"&gt; &lt;td style="text-align: justify; padding-bottom: 2.5pt;"&gt;Exercisable as of June 30, 2026&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;3,530,000&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;0.30&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;2.67&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;td style="border-bottom: Black 4pt double; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:fc_1096763520;"&gt;-&lt;/span&gt;&lt;/td&gt; &lt;td style="padding-bottom: 2.5pt; text-align: left;"&gt;&#160;&lt;/td&gt; &lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1206354996"
      decimals="0"
      id="ixv-5312"
      unitRef="uref_1895697896">4270000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_1206354996"
      decimals="2"
      id="ixv-5313"
      unitRef="uref_1489499025">0.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_886712638" id="ixv-5314">P4Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="cref_849656553"
      decimals="0"
      id="ixv-5315"
      unitRef="uref_1895697896">740000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="cref_849656553"
      decimals="2"
      id="ixv-5316"
      unitRef="uref_1489499025">0.3</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="cref_1962214993"
      decimals="0"
      id="ixv-5317"
      unitRef="uref_1895697896">3530000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="cref_1962214993"
      decimals="2"
      id="ixv-5318"
      unitRef="uref_1489499025">0.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="cref_849656553" id="ixv-5319">P2Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="cref_1962214993"
      decimals="0"
      id="ixv-5320"
      unitRef="uref_1895697896">3530000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="cref_1962214993"
      decimals="2"
      id="ixv-5321"
      unitRef="uref_1489499025">0.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="cref_849656553" id="ixv-5322">P2Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="cref_1962214993"
      decimals="0"
      id="ixv-5323"
      unitRef="uref_1895697896">3530000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="cref_1962214993"
      decimals="2"
      id="ixv-5324"
      unitRef="uref_1489499025">0.3</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="cref_849656553" id="ixv-5325">P2Y8M1D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="cref_1409363158"
      decimals="0"
      id="ixv-5326"
      unitRef="uref_1895697896">740000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="cref_1196774538"
      decimals="0"
      id="ixv-5327"
      unitRef="uref_1895697896">592000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="cref_360792440" id="ixv-3332">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 6: - SEGMENT REPORTING &lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;ASC 280, &#x201c;Segment Reporting,&#x201d; establishes standards for reporting information about operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker (&#x201c;CODM&#x201d;) in deciding how to allocate resources and in assessing performance. The Company&#x2019;s business is comprised of one operating segment. The Company&#x2019;s CODM is its &lt;span style="-sec-ix-hidden:fc_32209877;"&gt;Chief Executive Officer&lt;/span&gt; (&#x201c;CEO&#x201d;), who reviews financial information presented on a consolidated basis. The CODM uses consolidated net loss to measure segment profit or loss, to allocate resources and assess performance. Further, the CODM reviews and utilizes functional expenses (research and development and general and administrative) at the consolidated level to manage the Company&#x2019;s operations and evaluate return on total assets in deciding whether to invest in the development and expansion of the Company&#x2019;s consolidated operations.&lt;/span&gt; &lt;/p&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="cref_360792440"
      decimals="0"
      id="ixv-5328"
      unitRef="uref_1006700557">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription contextRef="cref_360792440" id="ixv-3340">The Company&#x2019;s CODM is its Chief Executive Officer (&#x201c;CEO&#x201d;), who reviews financial information presented on a consolidated basis. The CODM uses consolidated net loss to measure segment profit or loss, to allocate resources and assess performance.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <rvrc:SignificantEventsDuringTheReportingPeriodTextBlock contextRef="cref_360792440" id="ixv-3344">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 7: - SIGNIFICANT EVENTS DURING THE REPORTING PERIOD&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;On May 27, 2026, the Board of Directors of Revium Rx. (the &#x201c;Company&#x201c;) appointed Mr. Igor Bluvstein to serve as Chief Financial Officer of the Company and of its subsidiaries, effective immediately.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;In connection with this appointment, Mr. Arie Gordashnikov resigned from his position as Chief Financial Officer of the Company and of its subsidiaries on the same date. Mr. Gordashnikov&#x2019;s departure did not result from any disagreement with the Company on any matter relating to the Company&#x2019;s operations, policies or practices.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;Resignation of Ms. Inna Martin as Director, Chief Operating Officer and President&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;On June 10, 2026, Ms. Inna Martin resigned as a director and as Chief Operating Officer and President under a termination agreement with Revium RX Ltd.&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The Company recorded an expense of $45 thousand for termination benefits in the quarter, unpaid at June 30, 2026.&lt;/span&gt; &lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt; &lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;Modification of share-based awards. The agreement, approved by the Board on June 16, 2026, extended the exercise period of Ms. Martin&#x2019;s 2,440,000 vested options to September 30, 2028. As the options were fully vested, the incremental fair value of $111 thousand was recognized immediately in general and administrative expenses against additional paid-in capital, measured using Black-Scholes with a share price of $1.67 and volatility of 85%.&lt;/span&gt; &lt;/p&gt;</rvrc:SignificantEventsDuringTheReportingPeriodTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="cref_360792440"
      decimals="-3"
      id="ixv-5329"
      unitRef="uref_1230631324">45000</us-gaap:SeveranceCosts1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="cref_1895697896"
      decimals="0"
      id="ixv-5330"
      unitRef="uref_1895697896">2440000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
      contextRef="cref_1230631324"
      decimals="-3"
      id="ixv-5331"
      unitRef="uref_1230631324">111000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:SharePrice
      contextRef="cref_1489499025"
      decimals="2"
      id="ixv-5332"
      unitRef="uref_1489499025">1.67</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="cref_360792440"
      decimals="2"
      id="ixv-5333"
      unitRef="uref_1006700557">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SubsequentEventsTextBlock contextRef="cref_360792440" id="ixv-3378">&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&lt;span style="font-weight: bold;"&gt;NOTE 8: - SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1.25in; text-align: justify;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;&#160;&lt;/span&gt;&lt;/p&gt; &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; background-color: white;"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"&gt;The Company evaluated subsequent events through August 13, 2026, the date these interim condensed consolidated financial statements were issued, and determined that no events occurred that require recognition or disclosure in these interim condensed consolidated financial statements.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="cref_37844416" id="ixv-5334">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="cref_37844416" id="ixv-5335">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="cref_37844416" id="ixv-5336">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="cref_37844416" id="ixv-5337">false</ecd:Rule10b51ArrAdoptedFlag>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#fc_32597278"
          xlink:label="fc_32597278"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#fc_868368166"
          xlink:label="fc_868368166"
          xlink:type="locator"/>
        <link:footnote id="fref_1777688658" xlink:label="fref_1777688658" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">less than 1 thousand</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_32597278"
          xlink:to="fref_1777688658"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="fc_868368166"
          xlink:to="fref_1777688658"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
